Arbutin 3% (Beta --Glucopyranoside, 4-hydroxyphenyl) Cream as an Alternative Therapy for Melasma : a Double Blind Randomized Clinical Trial. 6
By: Jennie Ann B. De Jesus, Benedict DL Carpio, Eileen Regalado-Morales, Armelia Lapitan-Torres 4 0 16 [, ] | [, ] |
Contributor(s): 5 6 [] |
Language: Unknown language code Summary language: Unknown language code Original language: Unknown language code Series: ; 46Edition: Description: Content type: text Media type: unmediated Carrier type: volumeISBN: ISSN: 2Other title: 6 []Uniform titles: | | Subject(s): -- 2 -- 0 -- -- | -- 2 -- 0 -- 6 -- | 2 0 -- | -- -- 20 -- | | -- -- Melasma;Melasma Area Severity Index (MASI) -- Arbutin -- -- | -- -- -- 20 -- --Genre/Form: -- 2 -- Additional physical formats: DDC classification: | LOC classification: | | 2Other classification:| Item type | Current location | Home library | Collection | Call number | Status | Date due | Barcode | Item holds |
|---|---|---|---|---|---|---|---|---|
| Book | PLM | PLM Medical Library | Medical-Reserved | R97.P19 (Browse shelf) | Available | PER1888E |
ABSTRACT : Title of Paper : Arbutin 3% as an Alternative Therapy for Melasma. Objective: To demonstrate that arbutin is as efficacious as hydroquinone in the treatment of epidermal - type melasma. Specifically to compare the Melasma Area Severity Index (MASI) scores of those treated with arbutin versus hydroquinone, MASI scores across time and adverse reactions of Arbutin and hydroquinone. Design : Randomized double-blind clinical trial. Participants : Thirty - eight melasma patients at least 18 years old, recruited from Dermatology OPD, randomized to two intervention groups. Interventions : Identically prepared and packaged 10-gram creams of 3% arbutin or 4% hydroquinone applied over areas with melasma at bedtime. Sunblock with SPF 30 applied over face in mornings and before sun exposure, to wash face only with hypoallergenic soap and follow - up at 14 days and 30. Outcome Measures : MASI scores of participants using arbutin versus hydroquinone, MASI scores across time and adverse reactions to hydroquinone and arbutin. Results : Mean MASI scores between arbutin 3% cream and hydroquinone 4% cream not statistically different (Mann-Whitney U-Test, p.0.05). Clinical improvement after four weeks indicated by decrease in mean MASI scores across time statistically significant (Friedman test p=0.002). No difference in adverse reactions between intervention groups. None discontinued treatment in spite of adverse effects. Conclusions : Epidermal-type melasma clinically improved by arbutin 3% cream after four weeks. Difference in therapeutic efficacy and adverse reactions between arbutin 3% cream versus hydroquinone 4% cream not established. 56
5
5
There are no comments for this item.